Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiation Followed by Chemotherapy for Stage I/II Nasal NK Cell Lymphoma
NCT01321008Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2011
- Primary completion
- May 2013
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Covalent Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide, doxorubicin, vincristine, prednisone in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by University of Texas MD Anderson Cancer Center. Started May 2011; status: terminated.
02
Drugs
cyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT01321008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01321008.